FY2025 Earnings Estimate for RCKT Issued By Leerink Partnrs

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Investment analysts at Leerink Partnrs lifted their FY2025 earnings estimates for shares of Rocket Pharmaceuticals in a research note issued to investors on Monday, November 18th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will earn ($2.31) per share for the year, up from their prior forecast of ($2.46). The consensus estimate for Rocket Pharmaceuticals' current full-year earnings is ($2.85) per share.

Several other research firms have also recently weighed in on RCKT. Canaccord Genuity Group reiterated a "buy" rating and set a $39.00 price objective on shares of Rocket Pharmaceuticals in a report on Tuesday. Leerink Partners reduced their target price on shares of Rocket Pharmaceuticals from $46.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday. Scotiabank began coverage on Rocket Pharmaceuticals in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $50.00 price target on the stock. Needham & Company LLC reissued a "buy" rating and issued a $52.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday. Finally, Chardan Capital reaffirmed a "buy" rating and set a $62.00 price target on shares of Rocket Pharmaceuticals in a research report on Monday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $51.00.

Rocket Pharmaceuticals Stock Down 0.9 %

NASDAQ:RCKT opened at $13.04 on Thursday. Rocket Pharmaceuticals has a 1 year low of $12.62 and a 1 year high of $32.53. The stock has a 50-day moving average price of $17.38 and a two-hundred day moving average price of $19.98. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05.

Institutional Investors Weigh In On Rocket Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of RCKT. ProShare Advisors LLC raised its stake in Rocket Pharmaceuticals by 9.1% in the first quarter. ProShare Advisors LLC now owns 17,614 shares of the biotechnology company's stock valued at $475,000 after buying an additional 1,468 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Rocket Pharmaceuticals by 11.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,943,160 shares of the biotechnology company's stock valued at $79,290,000 after purchasing an additional 314,086 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Rocket Pharmaceuticals by 174.3% in the first quarter. Janus Henderson Group PLC now owns 2,606,016 shares of the biotechnology company's stock valued at $70,170,000 after purchasing an additional 1,656,111 shares during the last quarter. Harbor Capital Advisors Inc. raised its position in shares of Rocket Pharmaceuticals by 19.3% in the second quarter. Harbor Capital Advisors Inc. now owns 97,134 shares of the biotechnology company's stock valued at $2,091,000 after purchasing an additional 15,708 shares during the period. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Rocket Pharmaceuticals by 31.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,160 shares of the biotechnology company's stock worth $68,000 after buying an additional 764 shares during the last quarter. 98.39% of the stock is owned by institutional investors.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.